

Supplementary Table 1

Summary of the characteristics of the patients included into the study

	All patients (n = 185)	Patients on anti- depressant medication (n = 19)	Patients without anti-depressant medication (n = 164)	p-value
Age (years)	79.6 ±7.1	77.6 ±6.2	79.9 ±7.2	0.20
Females (proportion)	68.1 %	84.2 %	67.1 %	0.13
Smokers (proportion)	21.7 %	52.6 %	18.5 %	0.006*
Arterial hypertension	49.8 %	31.6 %	51.6 %	0.23
Other cardiovascular disorders	26.1 %	36.8 %	25.0 %	0.52
BMI (kg/m ²)	25.3 ±4.8	25.9 ±5.1	25.3 ±4.8	0.59
	All eyes (n = 205)	Eyes with anti- depressant medication (n = 19)	Eyes without anti- depressant medication (n = 184)	
Proportion of right eyes	48.8 %	26.3 %	50.5 %	0.04*
CNV type				0.13
- Occult	91 (44.6 %)	13 (68.4 %)	78 (41.6 %)	
- Minimally classic	20 (9.8 %)	2 (10.5 %)	17 (9.3 %)	
- Predominantly classic	56 (27.5 %)	3 (15.8 %)	52 (28.4 %)	
- RAP	37 (18.1 %)	1 (5.3 %)	36 (19.7 %)	
CNV size (DA)	1.9 ± 1.7	2.3 ± 2.7	1.8 ± 1.6	0.26
PED				
- Proportion > 200 µm	57 (27.8 %)	10 (52.6 %)	46 (25.0 %)	0.01*
- Baseline height (µm)	159 ± 168	209 ± 207	152 ± 159	0.16
- Height at Month-3 (µm)	94 ± 138	128 ± 167	88 ± 132	0.22
Atrophy				
- Baseline	43 (21.0 %)	5 (26.3 %)	38 (20.7 %)	0.56
- Month 24	107 (52.0 %)	7 (36.8 %)	100 (54.6 %)	0.14
VA (letters ETDRS)				
- Baseline	60.6 ± 16.6	64.0 ± 12.5	60.4 ± 17.0	0.37
- Change Month-3	+8.8 ± 10.3	+6.5 ± 8.9	+9.1 ± 10.3	0.30
- Change Month-12	+9.3 ± 11.9	+7.6 ± 8.1	+9.4 ± 12.2	0.54
- Change Month-24	+7.7 ± 14.6	+7.4 ± 7.8	+7.6 ± 15.2	0.94
CRT (µm)				
- baseline	389 ± 124	345 ± 128	394 ± 123	0.10
- change Month-3	-125 ± 114	-91 ± 116	-130 ± 114	0.16
- change Month-12	-128 ± 119	-106 ± 132	-131 ± 118	0.37
- change Month-24	-124 ± 128	-102 ± 147	-127 ± 127	0.44
Study drug				0.27
- Aflibercept	100 (48.8 %)	7 (37.8 %)	92 (50.0 %)	
- Ranibizumab	105 (51.2 %)	12 (63.2 %)	92 (50.0 %)	
Observed time to first recurrence (months)	Mean 3.8 ± 4.8 Quartiles 1/2/4	Mean 3.5 ± 5.6 Quartiles 1/1.5/2	Mean 3.9 ± 4.7 Quartiles 1/2/4	0.73
Number of injections until Month-24	Mean 14.1 ± 5.9 Quartiles 10/14/18	Mean 16.0 ± 6.0 Quartiles 13/16/19	Mean 13.8 ± 5.8 Quartiles 10/14/18	0.12
Injection interval (months)	Mean 3.6 ± 4.8 Quartiles 1.4/1.9/3.1	3.3 ± 5.4 Quartiles 1.2/1.6/2.2	3.6 ± 4.8 Quartiles 1.5/1.9/3.2	0.77

CNV = choroidal neovascular membrane; RAP = retinal angiomatous proliferation; DA = disc area; VA = visual acuity; BMI = body mass index; PED = pigment epithelium detachment; CRT = central retinal thickness; *p < 0.05

For 2 patients, the information about antidepressant medication was missing.